Accéder au contenu
Merck
  • The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.

Gastroenterology (2014-04-15)
Michael P Manns, John M Vierling, Bruce R Bacon, Savino Bruno, Oren Shibolet, Yaacov Baruch, Patrick Marcellin, Luzelena Caro, Anita Y M Howe, Christine Fandozzi, Jacqueline Gress, Christopher L Gilbert, Peter M Shaw, Michael P Cooreman, Michael N Robertson, Peggy Hwang, Frank J Dutko, Janice Wahl, Niloufar Mobashery
RÉSUMÉ

MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172 with peginterferon and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis. We performed a multicenter, double-blind, randomized, active-controlled, dose-ranging, response-guided therapy study. A total of 332 patients received MK-5172 (100, 200, 400, or 800 mg) once daily for 12 weeks in combination with PR. Patients in the MK-5172 groups received PR for an additional 12 or 36 weeks, based on response at week 4. Patients in the control group (n = 66) received a combination of boceprevir and PR, dosed in accordance with boceprevir's US product circular. At 24 weeks after the end of therapy, sustained virologic responses were achieved in 89%, 93%, 91%, and 86% of the patients in the groups given the combination of PR and MK-5172 (100, 200, 400, or 800 mg), respectively, vs 61% of controls. In the MK-5172 group receiving 100 mg, 91% of patients had undetectable levels of HCV RNA at week 4 and qualified for the short duration of therapy. The combination of MK-5172 and PR generally was well tolerated. Transient increases in transaminase levels were noted in the MK-5172 groups given 400 and 800 mg, at higher frequencies than in the MK-5172 groups given 100 or 200 mg, or control groups. Once-daily MK-5172 (100 mg) with PR for 24 or 48 weeks was highly effective and well tolerated among treatment-naive patients with HCV genotype 1 infection without cirrhosis. Studies are underway to evaluate interferon-free MK-5172-based regimens. ClinicalTrials.gov number: NCT01353911.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
L-Proline, from non-animal source, meets EP, USP testing specifications, suitable for cell culture
Sigma-Aldrich
L-Proline, BioUltra, ≥99.5% (NT)
SAFC
L-Proline
Sigma-Aldrich
L-Proline, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
L-Proline, 99%, FCC, FG
Sigma-Aldrich
Ribavirin, antiviral
USP
L-Proline, United States Pharmacopeia (USP) Reference Standard
Supelco
L-Proline, Pharmaceutical Secondary Standard; Certified Reference Material
L-Proline, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Proline, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Ribavirin, European Pharmacopoeia (EP) Reference Standard